A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Study sponsor: Faeth Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-24Actual
Enrollment · participants7Actual
Source updated2025-04-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.